Latest Conference Articles

November 4th 2021, 6:27pm

PER® Chemotherapy Foundation Symposium (CFS)

As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.

November 3rd 2021, 8:52pm

PER® Chemotherapy Foundation Symposium (CFS)

The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.

November 3rd 2021, 8:50pm

PER® Chemotherapy Foundation Symposium (CFS)

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

November 3rd 2021, 6:35pm

PER® Chemotherapy Foundation Symposium (CFS)

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

October 12th 2021, 7:56pm

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

September 23rd 2021, 2:00pm

ESMO Congress

The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.

September 22nd 2021, 7:00pm

ESMO Congress

Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.

September 22nd 2021, 3:10pm

International Workshop on CLL

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

September 21st 2021, 10:05pm

ESMO Congress

The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

September 21st 2021, 9:40pm

ESMO Congress

Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.

September 21st 2021, 9:37pm

International Workshop on CLL

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

September 21st 2021, 9:30pm

International Workshop on CLL

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

September 21st 2021, 7:27pm

ESMO Congress

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

September 21st 2021, 5:11pm

ESMO Congress

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

September 21st 2021, 3:50pm

ESMO Congress

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

September 21st 2021, 3:29pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

September 21st 2021, 2:24pm

International Workshop on CLL

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

September 21st 2021, 1:14pm

ESMO Congress

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

September 21st 2021, 1:14pm

ESMO Congress

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

September 20th 2021, 10:10pm

International Workshop on CLL

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.